Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 0.3417 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0.0629 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 0.3417 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 0.3417 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 0.3417 | 0.5323 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 0.3417 | 0.2433 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0101 | 0.4012 | 0.6248 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.2788 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0.0629 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.13 | 0.0716 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 0.3417 | 0.5323 |
Leishmania major | cytochrome P450 reductase, putative | 0.0081 | 0.2788 | 0.8159 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 0.3417 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0081 | 0.2788 | 0.8159 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 0.3417 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0101 | 0.4012 | 0.3116 |
Echinococcus multilocularis | geminin | 0.02 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0671 | 0.0045 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 0.3417 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 0.3417 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 0.3417 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 0.3417 | 0.2433 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 0.3417 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 0.3417 | 0.2433 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 0.3417 | 0.2433 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0081 | 0.2788 | 0.8159 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0056 | 0.13 | 0.2025 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0101 | 0.4012 | 0.3609 |
Brugia malayi | flavodoxin family protein | 0.0091 | 0.3417 | 0.5323 |
Treponema pallidum | flavodoxin | 0.0035 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.13 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0101 | 0.4012 | 0.3116 |
Schistosoma mansoni | hypothetical protein | 0.02 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0091 | 0.3417 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0101 | 0.4012 | 0.3609 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 0.3417 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0101 | 0.4012 | 0.3116 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 0.3417 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 0.3417 | 0.2975 |
Schistosoma mansoni | hypothetical protein | 0.02 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0056 | 0.13 | 0.2025 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 0.3417 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0141 | 0.642 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0141 | 0.642 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0101 | 0.4012 | 0.6248 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0101 | 0.4012 | 0.3609 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0101 | 0.4012 | 0.3116 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 0.3417 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 0.3417 | 0.5323 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.2788 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0141 | 0.642 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 0.61 uM | Inhibition of human nNOS expressed in HEK293 cells assessed as inhibition ionomycin induced nitric oxide production incubated for 24 hrs measured after 18 hrs of ionomycin challenge using 2,3-diaminonaphthalene by fluorescence assay | ChEMBL. | 20931971 |
EC50 (binding) | = 0.85 uM | Inhibition of human iNOS expressed in HEK293 cells assessed as inhibition of nitric oxide production after 18 hrs using 2,3-diaminonaphthalene by fluorescence assay | ChEMBL. | 20931971 |
EC50 (binding) | = 13 uM | Inhibition of human eNOS expressed in HEK293 cells assessed as inhibition A23187 induced nitric oxide production incubated for 24 hrs measured after 18 hrs of ionomycin challenge using 2,3-diaminonaphthalene by fluorescence assay | ChEMBL. | 20931971 |
T1/2 (ADMET) | > 120 min | Half life in mouse liver microsomes assessed as formation of oxidation product and glucuronide conjugate | ChEMBL. | 20931971 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.